NR4A1 and breast carcinoma: While endocrine therapy was first applied to patients with advanced breast cancer who are hormone receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER) negative, abemaciclib has been shown to be an effective monotherapy agent in this study [5].